Facon, T., Zweegman, S., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M. J., Pour, L., Marti, J., Basu, S., Cohen, Y. C., Matsumoto, M., Suzuki, K., Hulin, C., Grosicki, S., Beksac, M., Maiolino, A., Wang, J., Rowe, M., Carson, R. L., Usmani, S. Z. (2025). Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7516